Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Leaves Seniors More Cash To Spend On OTCs, IRI says

This article was originally published in The Tan Sheet

Executive Summary

Medicare Part D benefits will continue to influence spending on over-the-counter drugs and other consumer products in 2007 - with energy drink sales in particular growing - but more spending will move from independent retail stores to chains, research by Information Resources, Inc. shows

You may also be interested in...



Expensive Rx Drugs Put Spotlight On OTC Opportunity – Economist

Over-the-counter drug firms have a promising opportunity to market their products as alternatives to Rx drugs for consumers confronted with coverage gaps in Medicare Part D and private insurance plans, a Princeton University economics and public affairs professor advised industry executives

Expensive Rx Drugs Put Spotlight On OTC Opportunity – Economist

Over-the-counter drug firms have a promising opportunity to market their products as alternatives to Rx drugs for consumers confronted with coverage gaps in Medicare Part D and private insurance plans, a Princeton University economics and public affairs professor advised industry executives

Expensive Rx Drugs Put Spotlight On OTC Opportunity – Economist

Over-the-counter drug firms have a promising opportunity to market their products as alternatives to Rx drugs for consumers confronted with coverage gaps in Medicare Part D and private insurance plans, a Princeton University economics and public affairs professor advised industry executives

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100257

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel